(Re)defining biopharmaceutical

Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics-the core identity of the biotech industry and its products is at stake.

[1]  G. Walsh.  Biopharmaceuticals and biotechnology medicines: an issue of nomenclature. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[3]  H. Miller.  Biotech's defining moments. , 2007, Trends in biotechnology.

[4]  K. Katz.  ‘Biologics’: a clinically meaningless term , 2006, The British journal of dermatology.

[5]  R. Rader,et al.  Biopharmaceutical products in the U.S. and European markets , 2006 .

[6]  Simon Frantz,et al.  Pipeline problems are increasing the urge to merge , 2006, Nature Reviews Drug Discovery.